| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4583725
Max Phase: Preclinical
Molecular Formula: C27H29ClN4O4
Molecular Weight: 509.01
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CN(C)c1ccc(C(=O)N(CCC(=O)NCc2ccc(Cl)cc2)Cc2ccc(C(=O)NO)cc2)cc1
Standard InChI: InChI=1S/C27H29ClN4O4/c1-31(2)24-13-9-22(10-14-24)27(35)32(18-20-3-7-21(8-4-20)26(34)30-36)16-15-25(33)29-17-19-5-11-23(28)12-6-19/h3-14,36H,15-18H2,1-2H3,(H,29,33)(H,30,34)
Standard InChI Key: ZYLSOIIHIQAMBG-UHFFFAOYSA-N
Associated Targets(Human)
HDAC1 Tclin Histone deacetylase 1 (10854 Activities)
HDAC6 Tclin Histone deacetylase 6 (20808 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CHP-134 (45 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
IMR-32 (1082 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
SK-N-AS (237 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
NB1 (136 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
G55T2 (24 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 509.01 | Molecular Weight (Monoisotopic): 508.1877 | AlogP: 3.87 | #Rotatable Bonds: 10 |
| Polar Surface Area: 101.98 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 3 |
| #RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 9.05 | CX Basic pKa: 3.46 | CX LogP: 3.41 | CX LogD: 3.40 |
| Aromatic Rings: 3 | Heavy Atoms: 36 | QED Weighted: 0.28 | Np Likeness Score: -1.49 |
References
| 1. Reßing N, Marquardt V, Gertzen CGW, Schöler A, Schramm A, Kurz T, Gohlke H, Aigner A, Remke M, Hansen FK.. (2019) Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity., 10 (7): [PMID:31391882] [10.1039/C8MD00454D] |
Source
Source(1):